Next Article in Journal
Long-Term Effects of Ochratoxin A on the Glutathione Redox System and Its Regulation in Chicken
Next Article in Special Issue
Interaction of Potent Mitochondrial Uncouplers with Thiol-Containing Antioxidants
Previous Article in Journal / Special Issue
Mitochondrial Damage and Mitochondria-Targeted Antioxidant Protection in LPS-Induced Acute Kidney Injury
Open AccessArticle

Suppression of AMD-Like Pathology by Mitochondria-Targeted Antioxidant SkQ1 Is Associated with a Decrease in the Accumulation of Amyloid β and in mTOR Activity

1
Institute of Cytology and Genetics SB RAS, Pr. Lavrentyeva 10, Novosibirsk 630090, Russia
2
N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, 9 Lavrentieva Avenue, Novosibirsk 630090, Russia
*
Author to whom correspondence should be addressed.
Antioxidants 2019, 8(6), 177; https://doi.org/10.3390/antiox8060177
Received: 15 April 2019 / Revised: 10 June 2019 / Accepted: 12 June 2019 / Published: 14 June 2019
(This article belongs to the Special Issue Mitochondria-Targeted Antioxidants)
Age-related macular degeneration (AMD) is a major cause of irreversible visual impairment and blindness in developed countries, and the molecular pathogenesis of AMD is poorly understood. Recent studies strongly indicate that amyloid β (Aβ) accumulation —found in the brain and a defining feature of Alzheimer’s disease—also forms in the retina in both Alzheimer’s disease and AMD. The reason why highly neurotoxic proteins of consistently aggregate in the aging retina, and to what extent they contribute to AMD, remains to be fully addressed. Nonetheless, the hypothesis that Aβ is a therapeutic target in AMD is debated. Here, we showed that long-term treatment with SkQ1 (250 nmol/[kg body weight] daily from the age of 1.5 to 22 months) suppressed the development of AMD-like pathology in senescence-accelerated OXYS rats by reducing the level of Aβ and suppressing the activity of mTOR in the retina. Inhibition of mTOR signaling activity, which plays key roles in aging and age-related diseases, can be considered a new mechanism of the prophylactic effect of SkQ1. It seems probable that dietary supplementation with mitochondria-targeted antioxidant SkQ1 can be a good prevention strategy to maintain eye health and possibly a treatment of AMD. View Full-Text
Keywords: age-related macular degeneration; mitochondria-targeted antioxidant SkQ1; amyloid beta; mTOR; OXYS rats age-related macular degeneration; mitochondria-targeted antioxidant SkQ1; amyloid beta; mTOR; OXYS rats
Show Figures

Figure 1

MDPI and ACS Style

Muraleva, N.A.; Kozhevnikova, O.S.; Fursova, A.Z.; Kolosova, N.G. Suppression of AMD-Like Pathology by Mitochondria-Targeted Antioxidant SkQ1 Is Associated with a Decrease in the Accumulation of Amyloid β and in mTOR Activity. Antioxidants 2019, 8, 177.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop